The top 9 over­seas ac­counts in bio­phar­ma hold $133B in M&A fire­pow­er

Pic­tured (L-R): Stephen Ubl, CEO PhRMA; Ken Fra­zier, CEO Mer­ck; Robert Hug­in, Cel­gene chair­man; Robert Brad­way, CEO Am­gen on Jan­u­ary 31, 2017 at the White House af­ter meet­ing with Pres­i­dent Trump. An­drew Har­rer/Bloomberg via Get­ty

Dur­ing Am­gen’s Q1 dis­cus­sion with an­a­lysts on Wednes­day evening, CEO Bob Brad­way re­peat­ed one of the key themes in the land of Big Bio­phar­ma. Biotech val­u­a­tions are high, he not­ed, mak­ing it dif­fi­cult to ac­quire the kind of drug as­sets he’d like to lay his hands on.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER